These mice express the tamoxifen-inducible Cre-ERT2 fusion protein (Cre-ERT2) under the control of the promoter/enhancer regions surrounding the site where the enhancer trap transgene randomly inserted. These mice may be useful for generating conditional mutations for studying gain or loss of function and/or fate mapping in brain tissues.
Ronald L Davis, The Scripps Research Institute Florida
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Recombinase-expressing, Inducible) |
Mice hemizygous for this enhancer trap transgene are viable and fertile, with expression of the Cre-ERT2 fusion gene under control of the promoter/enhancer regions surrounding the site where the enhancer trap transgene randomly inserted. Cre recombinase activity is observed in brain tissues following tamoxifen administration. The donating investigators may not have assessed expression in tissues other than brain. When these enhancer trap transgenic mice are bred with mice containing a loxP-flanked sequence of interest, tamoxifen-inducible, Cre-mediated recombination will result in deletion of the floxed sequence(s) in cre-expressing tissues in the offspring.
Variable expression of a reporter gene has been reported in the feet, ears, and tail prior to induction of cre gene expression.
For characterization information, see images at the Allen Institute for Brain Science website (Et(cre/ERT2)7089Rdav images).
The Cre-ERT2 fusion protein (Cre-ERT2) consists of Cre recombinase fused to a triple mutant form of the human estrogen receptor; which does not bind its natural ligand (17β-estradiol) at physiological concentrations but will bind the synthetic estrogen receptor ligands 4-hydroxytamoxifen (OHT or tamoxifen) and, with lesser sensitivity, ICI 182780. Restricted to the cytoplasm, Cre-ERT2 can only gain access to the nuclear compartment after exposure to tamoxifen. To counteract the mixed estrogen agonist effects of tamoxifen injections, which can result in late fetal abortions in pregnant mice, progesterone may be coadministered.
An enhancer trap transgenic approach was used to generate these mice. The hsyn-bgi-Cre:ErT2-bGHpA transgene was designed with a human synapsin minimal promoter, a beta-globin intron, a CreERT2 fusion gene (Cre-ERT2; Cre recombinase fused to a G400V/M543A/L544A triple mutation of the human estrogen receptor ligand binding domain), and a bovine growth hormone polyA signal.
This transgene was injected into C57BL/6J embryos. Founder line 7089 was established on a C57BL/6J genetic background. Transgenic mice were subsequently bred for multiple generations with C57BL/6J mice and/or with Gt(ROSA)26Sortm1Sor mutant mice (backcrossed to C57BL/6 for at least 10 generations) prior to arrival at The Jackson Laboratory. Upon arrival, enhancer trap transgenic mice were selectively bred to C57BL/6J inbred mice (Stock No. 000664) to remove the Gt(ROSA)26Sortm1Sor mutation.
SNP (single nucleotide polymorphism) analysis performed by The Jackson Laboratory revealed that the Donating Investigator used C57BL/6N (5 of 5 markers segregating) in the development of the strain. Upon arrival at The Jackson Laboratory, the mice were crossed to C57BL/6J at least once to establish the colony.
Expressed Gene | cre/ERT2, Cre recombinase and estrogen receptor 1 (human) fusion gene, |
---|---|
Site of Expression | Cre recombinase activity is observed in brain tissues following tamoxifen administration. |
Allele Name | enhancer trap 7089, Ron Davis |
---|---|
Allele Type | Transgenic (Recombinase-expressing, Inducible) |
Allele Synonym(s) | |
Gene Symbol and Name | Et(cre/ERT2)7089Rdav, enhancer trap 7089, Ron Davis |
Gene Synonym(s) | |
Promoter | N/A, not available, |
Expressed Gene | cre/ERT2, Cre recombinase and estrogen receptor 1 (human) fusion gene, |
Site of Expression | Cre recombinase activity is observed in brain tissues following tamoxifen administration. |
Strain of Origin | C57BL/6J |
Chromosome | UN |
Molecular Note | An enhancer trap transgenic approach was used to generate these mice. The hsyn-bgi-cre:ERT2-bGHpA transgene was designed with the human synapsin minimal promoter (hsyn) minimal promoter driving a cre-ERT2 fusion gene (cre recombinase fused to a G400V/M543A/L544A triple mutation of the human estrogen receptor ligand binding domain).A beta globin intron separates the promoter from the cre gene and the bovine growth hormone polyadenylation signal follows the cre sequence. This transgene was injected into C57BL/6J embryos. Founder line 7089 was established on a C57BL/6J genetic background. |
When maintaining a live colony, transgenic carrier mice may be bred together, to wildtype (noncarrier) siblings, or to C57BL/6J inbred mice (Stock No. 000664).
When using the B6(129S4)-Et(cre/ERT2)7089Rdav/J mouse strain in a publication, please cite the originating article(s) and include JAX stock #010690 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or non-carrier for Et(cre/ERT2)7089Rdav |
Frozen Mouse Embryo | B6(129S4)-Et(cre/ERT2)7089Rdav/J | $2595.00 |
Frozen Mouse Embryo | B6(129S4)-Et(cre/ERT2)7089Rdav/J | $2595.00 |
Frozen Mouse Embryo | B6(129S4)-Et(cre/ERT2)7089Rdav/J | $3373.50 |
Frozen Mouse Embryo | B6(129S4)-Et(cre/ERT2)7089Rdav/J | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.